Loading...
•
Sep 30, 2023
Vir Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023.
Key Takeaways
Vir Biotechnology reported a net loss of $163.4 million for the third quarter of 2023, with total revenues of $2.6 million. The company had $1.7 billion in cash, cash equivalents, and investments as of September 30, 2023. They also made a $67.0 million payment to GSK for excess sotrovimab supply and manufacturing capacity.
Continued to execute on multiple clinical stage programs and look forward to sharing Phase 2 data from chronic hepatitis B and chronic hepatitis delta trials at AASLD.
Initiated a new Phase 1 HIV T cell vaccine clinical trial.
Secured non-dilutive funding from the U.S. government to advance next generation COVID-19 mAb through Phase 1.
Expanding strategic focus to autoimmune diseases and immuno-oncology.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...